On this week’s podcast, Dr Louise is joined by Dr Ashley Winter, a urologist and sexual medicine specialist, and Dr Sarah Glynne, a GP and menopause specialist who is a member of the research team at Newson Health and chairs a working party that promotes access to evidence-based menopause care for patients with breast cancer. They discuss Fezolinetant – brand name Veoza – a new drug recently approved in the UK and other countries to treat moderate to severe hot flushes in menopausal women aged 45 to 60 years. You can read an article about fezolinetant on the balance website here. Related articles Lederman S., Ottery F.D., Cano A., Santoro N., Shapiro M., Stute P., et al. (2023) 'Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study', Lancet, 401(10382):1091-102. doi.org/10.1016/S0140-6736(23)00085-5 Johnson K.A., Martin N., Nappi R.E., Neal-Perry G., Shapiro M., Stute P., et al. (2023), 'Efficacy and safety of fezolinetant in moderate to severe vasomotor symptoms associated with menopause: a Phase 3 RCT', J Clin Endocrinol Metab, 108(8):1981-97. Doi:10.1210/clinem/dgad058 Douxfils J., Beaudart C., Dogne J.M. (2023), 'Risk of neoplasm with the neurokinin 3 receptor antagonist fezolinetant', Lancet, 402(10413):1623-5. doi.org/10.1016/S0140-6736(23)01634-3 Follow Dr Ashley Winter on X and Instagram @ashleygwinter Follow Dr Sarah Glynne on Instagram @sarahglynne Click here to find out more about Newson Health

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.